Clear Smiles, Clear Recognition: Leaside Orthodontic Centre Honoured with 2025 Consumer Choice Award in Toronto Central
Leaside Orthodontic Centre is led by Dr. Emel Arat, D.D.S., Ph.D., F.R.C.D.(C), a certified orthodontic specialist renowned for her expertise in clear aligners, custom clear braces, and self-ligating braces. Grounded in a modern, patient-focused philosophy and supported by a team of skilled professionals, the clinic delivers tailored treatment plans designed to create confident and healthy smiles.
A Legacy of Expertise and Innovation
Since its inception, Leaside Orthodontic Centre has positioned itself at the forefront of orthodontic care. By employing state-of-the-art technologies-such as intraoral scanning, digital treatment planning, and precision-fabricated LightForce clear braces-Dr. Arat and her team consistently deliver efficient, minimally invasive treatments with predictable results.
'Our passion is helping patients achieve both beautiful and healthy smiles in an environment that feels supportive and stress-free,' said the Leaside Orthodontic Centre team. 'Receiving the Consumer Choice Award is a testament to our commitment to customized care and clinical excellence.'
Comprehensive Services with Patient Comfort in Mind
Leaside Orthodontic Centre offers a full suite of orthodontic solutions, including: Clear aligners, featuring the latest systems for subtle, removable treatment
Custom clear (ceramic) braces for patients wanting discreet but fixed options
Self-ligating braces, which reduce friction and may shorten treatment time
Each treatment is personalized based on detailed assessment and patient preferences, ensuring optimum comfort, functionality, and aesthetics.
Technology-Driven, Patient-Centered Care
Utilizing digital intraoral scanners, advanced lab-fabricated braces, and virtual planning tools, Leaside Orthodontic Centre enhances precision, comfort, and efficiency. These innovations reduce manual discomfort, minimize in-office adjustment needs, and support sustainable treatment through less material waste.
The clinic also integrates paperless forms, and seamless communication tools-enhancing convenience and reducing environmental impact, in line with modern healthcare expectations.
Award-Winning Recognition Based on Trust and Quality
The Consumer Choice Award reflects independent market research and verified patient feedback, assessing brand reputation, service excellence, and satisfaction. Leaside Orthodontic Centre's win underscores the clinic's strong rapport with patients across Toronto Central, their trusted clinical outcomes, and consistent service delivery.
'This award is especially meaningful because it comes from the community we serve,' added the Leaside Orthodontic Centre team. 'We're honoured to have our efforts acknowledged and look forward to continuing to exceed expectations.'
Invested in Toronto's Smiles and Strengthening Community Connections
The clinic actively engages in its neighbourhood, participating in dental outreach, educational workshops, supporting local schools and wellness initiatives in Leaside and surrounding areas. Through these efforts, Leaside Orthodontic Centre contributes to broader community health and well-being.
Looking forward, the clinic plans to expand its offerings with new digital follow-up tools, enhanced pediatric orthodontic programmes, and even more patient education resources. The commitment to innovation, expertise, and positive patient impact remains stronger than ever.
To explore Leaside Orthodontic Centre's treatments and schedule a consultation, CLICK HERE or visit www.leasideorthodonticcentre.ca .
About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.
Contact Information:
Sumi Saleh
Communications Manager
[email protected]
SOURCE: Consumer Choice Award
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Breastfeeding could help prevent early puberty in girls and boys, South Korean study finds
Girls and boys who were exclusively breastfed during their first four to six months showed a reduced risk of early puberty, according to a large new study from South Korea that Canadian doctors say could apply here. The study, published in Monday's issue of JAMA Network Open, looked back at the diets and development of more than 300,000 children from 2007 to 2020, based on data from checkups at four to six months of age and before six years. Worldwide, puberty has increasingly begun earlier in kids. Called "central precocious puberty," it's linked to an increased risk of health problems in adulthood, like heart disease, cancer and diabetes, as well as mental health issues like depression and anxiety. The researchers believe that kids who are exclusively breastfed are less likely to develop childhood obesity, a major predisposing factor of early puberty. However, experts note that many mothers face challenges in breastfeeding, which they say should be addressed on a structural level. "The take-home message should be, for parents or to-be parents, that breastfeeding has multiple beneficial health effects for their children," said Dr. Sonia Anand, associate vice-president of global health at McMaster University, who was not involved in the study. "And the second message is it is not always easy to do." Long-term benefits of breastfeeding About 46 per cent of the babies in the South Korean study were exclusively breastfed, more than a third had formula and nearly 20 per cent had both. "The idea is that breastfed kids are less likely to have extra weight and that's the mechanism whereby they're more protected from developing early puberty," said Dr. Kaberi Dasgupta, a professor of medicine and physician scientist at the McGill University Health Centre, who also was not involved in the study. Boys who were fed just formula had a 16 per cent increased risk of early puberty compared with their peers who were only fed breast milk, the researchers found. For exclusively formula-fed girls, the association jumped to 60 per cent. For mixed-fed boys, it was 14 per cent higher, compared with 45 per cent for girls. The researchers noted some caveats to their study. The participants self-reported how long they breastfed their children, for example. It also couldn't include genetic factors like maternal age of puberty. The early part of life is a key time, as that's when a lot of disease risk is set, wrote doctors Lin Yang and Shengxu Li. Though they weren't involved in the study, they wrote an accompanying journal commentary. "Disease starts early, so should its prevention," they said. Dasgupta says there's no reason to think the findings would be different in Canada. Preventing early puberty can also help kids in other ways, she adds. "The earlier your puberty, the shorter you may become," she said. "There's also the stigma around having early signs of being an adult when you're still a kid. Other kids may tease you." Supporting mothers instead of shaming Yang and the researchers say that instead of putting pressure on new moms, a society-wide approach is important. That includes stronger parental leave policies, workplace accommodations like a private space to breastfeed and lactation support services. "I think policy support, raised awareness, as well as creating the environment for women to be able to [breastfeed] is very important," Yang told CBC News. Sleep patterns, physical activity levels and screen time could also be increasing childhood obesity and early puberty rates, Yang and Li wrote in their commentary, as well as environmental pollutants like endocrine disruptors, though she acknowledged there isn't good data on that. In Canada, about 91 per cent of parents start out breastfeeding. About 38 per cent of parents breastfed exclusively for at least six months, Statistics Canada reported in 2024. Of those who stopped before six months, reasons included not having enough breast milk, finding breastfeeding difficult and the child weaning themself off of it. "I think the wrong takeaway and the wrong approach is to shame mothers who try to breastfeed but can't continue," Anand said. Breastfeeding is one factor among many that can influence weight gain in kids. Lifestyle choices like limiting fast food and cooking with more vegetables and lean proteins can also help prevent childhood obesity, doctors say. While the South Korean study doesn't prove that formula feeding causes early puberty, the researchers had a robust data set and the associations are plausible, she said. Anand's own research demonstrated early breastfeeding and for at least six months was associated with lower levels of excess body fat in children at age three. She says she'd like to see other large studies show similar findings to the South Korean to nail down cause and effect. Studies looking at how genes are tied to precocious puberty could also help, she said.
Yahoo
an hour ago
- Yahoo
Fever's Sophie Cunningham breaks silence on brutal MRI results for knee injury
Fever's Sophie Cunningham breaks silence on brutal MRI results for knee injury originally appeared on The Sporting News The Indiana Fever can't stay healthy. The latest bad news came Tuesday, when standout wing Sophie Cunningham was ruled out for the rest of the season with a right knee injury. The Fever announced that an MRI revealed a right MCL tear for Cunningham. "The Indiana Fever announced today that guard Sophie Cunningham will miss the remainder of the 2025 WNBA season after suffering an injury during the team's game at the Connecticut Sun on Sunday afternoon," the team announced. "Cunningham sustained a season-ending injury in her right knee during the second quarter of the game and is expected to make a full recovery." After the Fever announced Cunningham's prognosis, she chimed in on X: Cunningham celebrated her birthday on Saturday, turning 29 years old. She was then injured on Sunday in a collision with Bria Hartley. And now on Tuesday, she knows her season is over. The Fever signed Shay Peddy to a hardship contract to take Cunningham's roster spot. Indiana has lost Cunningham, Sydney Colson and Aari McDonald to season-ending injuries in the past two weeks. The Fever also haven't had Caitlin Clark for the last 13 games due to a lingering groin issue. Cunningham's popularity blossomed this season with the Fever as she averaged 8.6 points per game and knocked down 43.2% of her 3s while filling a physical enforcer role on the court. Now, though, the Fever will have to navigate the rest of the season without her. MORE: The latest on Caitlin Clark's injury
Yahoo
2 hours ago
- Yahoo
Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy. Unsold completed new-build inventory is so high this $34B homebuilder is turning to investors 'Job hugging' is the newest career trend: Here's what it means—and why Gen Z is into it Spotify just redesigned the way you'll 'listen' to audiobooks According to a press release posted early on August 18, GoodRx has struck a deal with the pharmaceutical giant Novo Nordisk to sell its popular semaglutide medications, Ozempic and Wegovy, for just $499 per month to 'eligible self-paying customers.' GoodRx doesn't sell or dispense any drugs itself, but rather provides savings and coupons that can be applied in pharmacies. Its exclusive Ozempic and Wegovy offerings, available starting today, are the lowest out-of-pocket costs for the medications available on the market. The news comes just weeks after Novo Nordisk cut ties with the telehealth company Hims & Hers Health (NYSE: HIMS) over claims that Hims & Hers was selling 'knockoff' versions of Wegovy. It's a dispute that reflects a broader discussion around whether compounded semaglutide drugs—or non-FDA approved versions of brand-name medicines—are a violation of intellectual property laws. As of this writing, GoodRx's stock is up by more than 30% since market close. Here's what to know about Novo Nordisk's latest partnership and its ongoing legal battles against compounded GLP-1s. GoodRx's collaboration with Novo Nordisk In the last year alone, GoodRx reports that nearly 17 million people visited the site searching for information and savings on GLP-1 medications—a 22% increase from the previous year. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' Wendy Barnes, GoodRX president and CEO, said in the press release. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them.' In the past, a spokesperson told Fast Company, GoodRx has worked with both Novo Nordisk and its competitor Eli Lilly to offer commercially insured patients manufacturer savings cards on GLP-1s. The company has also offered savings on other types of weight loss/diabetes treatments, including Contrave, Dexcom G7, Lantus, and Qsymia. However, this is the first time that GoodRx has offered a cash price for a GLP-1. The $499 monthly self-pay cost will be available at more than 70,000 retail locations nationwide. Novo Nordisk's current legal battles over compounded GLP-1s So far, investors' response to GoodRx's new collaboration has been overwhelmingly positive. It stands in sharp contrast to Hims & Hers' recent breakup with Novo Nordisk, which caused the telehealth company's share prices to plummet in late June. Hims & Hers and Novo Nordisk parted ways over Hims & Hers' offering of compounded versions of Wegovy. Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand-name drugs using their active ingredient, semaglutide, and sell them at a lower cost. However, Hims & Hers has continued to sell its compounded version of Wegovy long after the FDA lifted the shortage back in February. Now, Novo Nordisk is arguing that these compounded drugs are both a violation of its intellectual property and potentially dangerous to patients, due to their lack of FDA approval. Early this month, Novo Nordisk announced 14 new lawsuits against small pharmacies, telehealth providers, and weight-loss clinics over compounded versions of Ozempic and Wegovy—bringing its total cases filed on the matter up to more than 130 in 40 states. Experts say that federal compounding laws are just vague enough to allow for various interpretations, meaning that Novo Nordisk's current legal challenges could shape the way courts interpret those boundaries in the future. In a statement to Yahoo Finance, Barnes offered a clear look into GoodRx's stance on compounded drugs: 'There's no question we could have tried to do something sooner from a compounded alternative pathway, but we have been very clear in our belief that it needed to be FDA-approved, lawfully approved. It just wasn't a pathway that we were going to support,' she said. This post originally appeared at to get the Fast Company newsletter:
